MktsMarkets

Vertex Pharmaceuticals Incorporated
NASDAQ: VRTXKey statistics
VRTX News
Stories mentioning VRTX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 2,986,900 | 3,190,000 | 3,076,400 | 2,964,700 | 2,770,200 | 2,912,000 | 2,771,900 | 2,645,600 |
| Cost of Goods Sold | 392,800 | 466,000 | 414,800 | 407,500 | 363,000 | 423,400 | 392,600 | 371,900 |
| Gross Profit | 2,594,100 | 2,724,000 | 2,661,600 | 2,557,200 | 2,407,200 | 2,488,600 | 2,379,300 | 2,273,700 |
| Operating Expenses | ||||||||
| Research & Development | ||||||||
| Sales General & Admin | 493,700 | 487,000 | 445,100 | 424,600 | 396,400 | 377,600 | 371,800 | 372,200 |
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | 1,138,100 | 1,205,900 | 1,186,200 | 1,151,100 | 630,100 | 1,026,000 | 1,116,300 | (3,514,700) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 0.00 | 6,500 | (9,800) | 13,200 | (17,600) | (14,900) | (16,900) | (23,100) |
| Pretax Income | 1,252,900 | 1,331,000 | 1,298,800 | 1,283,000 | 730,400 | 1,136,500 | 1,224,100 | (3,391,200) |
| Tax Provision | 221,500 | 139,900 | 215,900 | 250,100 | 84,100 | 223,500 | 178,700 | 202,400 |
| Net Income (Loss) | 1,031,400 | 1,191,100 | 1,082,900 | 1,032,900 | 646,300 | 913,000 | 1,045,400 | (3,593,600) |
| Earnings Per Share (Basic) | 4.06 | 4.66 | 4.24 | 4.02 | 2.52 | 3.54 | 4.05 | (13.92) |
| Earnings Per Share (Diluted) | 4.02 | 4.62 | 4.20 | 3.99 | 2.49 | 3.54 | 4.01 | (13.92) |
| Weighted Average Shares Outstanding (Basic) | 254,100 | 255,700 | 255,600 | 256,700 | 256,900 | 257,900 | 258,000 | 258,100 |
| Weighted Average Shares Outstanding (Diluted) | 256,300 | 258,000 | 257,600 | 258,900 | 259,500 | 257,900 | 261,000 | 258,100 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About VRTX
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a stock listed on the Nasdaq Stock Market under the ticker symbol VRTX. It last traded at $550.87 (Nov 9, 2026, 9:30 AM ET), up 0.7% on the day. That gives Vertex Pharmaceuticals a market capitalisation of $139.5B and a price-to-earnings ratio of 31.7.
Over the past 52 weeks VRTX has traded between $410.50 and $568.67.
Revenue for the quarter ended Mar 31, 2026 was $3.0B; net income $1.0B. Revenue was up 7.8% from $2.8B in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $3.0B | $1.0B | 34.5% |
| Dec 31, 2025 | $3.2B | $1.2B | 37.3% |
| Sep 30, 2025 | $3.1B | $1.1B | 35.2% |
| Jun 30, 2025 | $3.0B | $1.0B | 34.8% |
From Vertex Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…